Sites of progression in
ALK
+ NSCLC
Scagliotti, et al. ESMO 2016 (Abs. LBA42); Kim, et al. Lancet Oncol 2016 17(4): 452–63; Crino, et al. J Clin Oncol 2016 34(24): 2866–73
Kim, et al. ASCO 2016 (Abs. 9007); Shaw, et al. Lancet Oncol 2016 17(2):234–42; Ou, et al. J Clin Oncol 2015 34(7): 661–8
Solomon, et al. N Engl J Med 2014 371(23): 2167–77; Felip, et al. ESMO 2016 (Abs. 1208O)
ALK
inhibitor-naive
Post-ALK
inhibitor
31–40%
58–71%
31–44%
42–58%
27–36%
37–42%
75%
34–68%
Bone
Brain
Liver
Lung
